Tizanidine Dosing in Chronic Kidney Disease
Tizanidine clearance is reduced by more than 50% in patients with severe renal impairment (creatinine clearance <25 mL/min), requiring cautious use with reduced individual doses rather than decreased dosing frequency. 1
Dosing Recommendations by Renal Function
Mild to Moderate Renal Impairment (CrCl ≥25-30 mL/min)
- No specific dose adjustment is mandated in the FDA labeling for mild to moderate impairment
- However, use with caution as pharmacokinetic changes begin at this level
- Monitor closely for adverse effects (hypotension, sedation, dizziness, dry mouth) as indicators of drug accumulation 1
Severe Renal Impairment (CrCl <25 mL/min)
- Reduce individual doses during titration rather than extending dosing intervals 1
- Start at the lowest possible dose (2 mg) and titrate slowly
- If higher total daily doses are needed, increase individual dose amounts rather than frequency 1
- Maximum monitoring is essential: The prolonged drug effect duration necessitates close observation for hypotension, excessive sedation, and bradycardia 1
Critical Safety Considerations
Hypotension Risk
Tizanidine causes dose-related hypotension in two-thirds of patients at 8 mg doses, with peak effects at 2-3 hours post-dose 1. In renal impairment, this effect is prolonged and intensified due to reduced clearance. The risk of orthostatic hypotension and syncope increases substantially 1.
Hepatotoxicity Monitoring
Approximately 5% of patients develop transaminase elevations >3x upper limit of normal 1. Monitor ALT/AST at baseline and monthly for the first 6 months, particularly in CKD patients who may have altered drug metabolism 1.
QT Prolongation
Tizanidine blocks the rapid delayed rectifier potassium current (IKr), causing QT prolongation 2. This risk is amplified in renal impairment due to drug accumulation. Obtain baseline ECG and monitor for QTc changes, especially if combining with other QT-prolonging medications 2.
Practical Dosing Algorithm
For CrCl <25 mL/min:
- Start with 2 mg once daily (preferably at bedtime to minimize hypotension risk)
- Check blood pressure (supine and standing), heart rate, and assess sedation at 1-2 hours post-dose
- If tolerated after 3-7 days, may increase to 2 mg twice daily
- Subsequent increases: Add 2 mg to individual doses rather than adding doses (e.g., 4 mg twice daily before 2 mg three times daily)
- Avoid exceeding 8 mg per individual dose in severe renal impairment
- Monitor liver function tests monthly for 6 months, then quarterly
For CrCl 25-50 mL/min:
- Standard titration may be used but with extended intervals between dose increases (5-7 days rather than 2-4 days)
- Monitor for cumulative adverse effects more frequently than in patients with normal renal function
Common Pitfalls to Avoid
- Do not use standard dosing schedules from the package insert without adjustment in severe CKD—the 50% reduction in clearance mandates dose modification 1
- Avoid combining with other alpha-2 agonists (clonidine) or antihypertensives without careful blood pressure monitoring 1
- Do not abruptly discontinue: Taper slowly to prevent rebound hypertension and tachycardia, which may be more severe in CKD 1
- Women on oral contraceptives have 50% lower tizanidine clearance; this effect is additive to renal impairment, requiring even more conservative dosing 1
Drug Interactions in CKD
Avoid or use extreme caution with:
- CYP1A2 inhibitors (ciprofloxacin, fluvoxamine): These dramatically increase tizanidine levels and proarrhythmic risk, particularly dangerous in CKD 2
- Alcohol: Increases AUC by 20% and Cmax by 15%, with additive CNS depression 1
- Other CNS depressants (baclofen, benzodiazepines): Additive sedation may mask signs of tizanidine toxicity 1
Monitoring Parameters
- Blood pressure (supine and standing): Before each dose increase and at 1-2 hours post-dose
- Heart rate: Watch for bradycardia, especially with beta-blockers
- Renal function: Every 3-6 months or with clinical changes
- Liver enzymes: Monthly for 6 months, then quarterly
- Clinical assessment: Sedation level, muscle tone response, functional status
The limited long-term safety data at higher doses (>24 mg/day) combined with significantly reduced clearance in CKD makes conservative dosing mandatory 1. The goal is achieving spasticity control while avoiding the serious cardiovascular and hepatic complications that are amplified by renal impairment.